FRM
NAMS icon

Fox Run Management’s NewAmsterdam Pharma NAMS Stock Holding History

Fox Run Management’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.02M Buy
+59,477
New +$1.96M 0.33% 25
2026
Q1 		– Sell
-9,798
Closed -$344K – 1125
2025
Q4 		$344K Buy
+9,798
New +$357K 0.05% 649

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Fox Run Management's NAMS Position: Q2 2026 in Review

Fox Run Management opened a new position in NewAmsterdam Pharma (NAMS) in Q2 2026: 59,477 shares worth $2.02M. The stake represents 0.33% of the portfolio and ranks #25 among its holdings. This is a return to the name: Fox Run Management previously reported a position in NAMS as recently as Q4 2025.

Fox Run Management first reported a position in NAMS in Q4 2025 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Fox Run Management held 59,477 shares of NewAmsterdam Pharma worth $2.02M as of Q2 2026.
  • NewAmsterdam Pharma was a new Fox Run Management position in Q2 2026.
  • NewAmsterdam Pharma made up 0.33% of Fox Run Management's portfolio in Q2 2026, its #25 holding.
  • Fox Run Management first reported a position in NewAmsterdam Pharma in Q4 2025 and has held it in 2 quarters since.
  • 195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.